Dr Zongli ZHENG Participated in Panel Discussion on Venture Fund Support to Start-ups at Asia Summit on Global Health 2024
[May 17, 2024] – GenEditBio Limited (“GenEditBio”), a biotech company focuses on precision genome editing to provide affordable “precision DNA surgery” for genetic diseases with unmet needs, is pleased to announce the participation of our Co-Founder and Chairman, Zongli ZHENG, PhD, as an invited guest speaker on a panel discussion on venture fund support to start-ups at the Asia Summit on Global Health (ASGH) on May 17, 2024, Hong Kong, China.
During the panel discussion, Dr ZHENG, along with Mr Nicholas Chan, MH, JP, Panel Chair and Chairman of the Innovation and Technology Venture Fund (ITVF) Advisory Committee of the Government of the HKSAR, and other invited distinguished guests, had the opportunity to share their own experience and insights into how ITVF and VC funds assisted local innovation and technology (I&T) start-ups towards success.
“We are tremendously grateful for the investment and positive impact brought by ITVF on the growth and strategic initiatives of GenEditBio”, said Dr ZHENG. The panel also discussed global trends of healthcare market and shared their insights on creating a more vibrant I&T ecosystem in Hong Kong and beyond.
(Fourth right) Co-Founder and Chairman of GenEditBio, Zongli ZHENG, PhD, participates today (May 17) as an invited guest speaker on a panel discussion on venture fund support to start-ups at the ASGH 2024. (Photo: Kenneth Ho/GenEditBio)
(Right) Co-Founder and Chairman of GenEditBio, Zongli ZHENG, PhD, speaks today (May 17) at a fireside chat at the ASGH 2024 panel discussion. (Photo: Kenneth Ho/GenEditBio).
About ASGH
The ASGH, jointly organized by the Government of the HKSAR and the Hong Kong Trade Development Council, is Asia's premier event on health innovation and investment. It serves as a dynamic platform bringing together policymakers, healthcare experts, academia, business leaders, start-ups, and investors from around the world to exchange insights and collaborate on the diverse healthcare sector.
About GenEditBio
Established in 2021 and headquartered in Hong Kong, China, GenEditBio is a gene therapy start-up company with an overarching strategic goal of providing potentially curative, once-and-done and programmable in vivo genome editing-based therapeutic solutions (dubbed “DNA surgery”) with high safety profile, unmatched precision, and affordable access for genetic diseases that currently lack cures or effective treatments. The Company’s core areas of focus include novel Cas nuclease discovery and safe and efficient cargo delivery utilizing LNPs (lipid nanoparticles) and ePDVs (engineered protein delivery vehicles). We have research laboratories and supporting offices in Hong Kong, Beijing, and Boston. GenEditBio is financially backed by top-tier life science investors, including Qiming Venture Partners, Fangyuan Capital, Center Ventures, Lumosa Therapeutics, Innovation and Technology Venture of the HKSAR Government, and HKSTP Venture Fund.
Contact
bd@geneditbio.com
